ONLINE APPENDIX - Supplementary Materials Experimental Procedures

Immunofluorescence staining and flowcytometric analysis— To determine the purity of isolated CD4⁺ T lymphocytes, CD4⁺ T cells from the spleen, thymus and LN were treated with Fc receptor blocking CD16/32 antibody and subsequently incubated with PE anti-CD3, APC anti-CD4 or PerCP anti-CD8 antibodies (BioLegend, San Diego, CA) for 30 mins at 4°C. Following washing steps, cells were analyzed with an LSRII and a FACS Diva software (BD Biosciences, San Diego, CA).

Rac1 pull-down activation assay— GTP-bound Rac1 was measured using a Rac1 activation assay kit (Upstate Technology) according to the manufacturer's instructions. Briefly, DPP-IV (100 mU/ml), GIP (100 nM) or GLP-1 (100 nM) treated CD4⁺ T lymphocytes were lysed in ice-cold magnesium lysis buffer and cleared with glutathione-agarose beads. Cell extracts were then incubated with p21-binding domain (PBD, residues 67-150) of human PAK-1 agarose beads, the resulting beads were resuspended and separated on 15 % sodium dodecyl sulfate (SDS)/polyacrylamide gel. GTP-bound Rac1 was detected using an anti-Rac1 antibody.

Preparation of nuclear extracts— Nuclear proteins were isolated as described by Schreiber *et al* (1). Briefly, LN CD4⁺T cells were washed with PBS, and disrupted with 200 μ l ice-cold buffer A (10 mM HEPES pH 7.9, 10 mM KCl, 1.5 mM MgCl₂, 1 mM EDTA, 1 mM dithiothreitol, 0.1 % Nonidet P40 and protease inhibitors). Following centrifugation, the resulting pellet was re-suspended in 20 μ l buffer B (20 mM HEPES, pH 7.9, 400 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol, 20 % glycerol and protease inhibitors) and incubated on ice for 10 min. After clarification of the mixture by centrifugation, the supernatant (nuclear extract) was collected and subjected to an NF κ B transcription factor activity assay.


*NF*κ*B* transcription factor activity assay— An NFκB transcription factor activity assay kit (Millipore, MA) was used to measure DNA binding activity of NFκB transcription factor in nuclear extracts of LN CD4⁺T cells, according to the manufacturer's protocols. Briefly, nuclear extracts of LN CD4⁺ T cells were incubated with biotinylated oligonucleotide containing the consensus sequence for NFκB binding (5'-GGGACTTTCC-3'), and the biotinylated oligonucleotide bound by active NFκB protein was immobilized. The bound NFκB transcription factor subunit p50, was detected with a specific primary antibody, α-NFκB p50 (active form), and subsequently with an HRPconjugated secondary antibody. Nuclear NFκB activity is presented as relative activity normalized to protein concentration.

Western blot analysis— Total cellular or nuclear extracts were separated on a 15% sodium dodecyl sulfate (SDS)/polyacrylamide gel and transferred onto nitrocellulose membranes (Bio-Rad). Probing of the membranes was performed with antibodies against phospho-Cofilin (Serine3), Cofilin, Phospho-Ezrin (Threonine567)/Radixin (Threonine564)/Moesin (Threonine558), Ezrin/Radixin/Moesin, phospho-VASP (Serine157), phospho-VASP (Serine239), VASP, phospho-IkBa (Ser32), IkBa, phospho-NFκB p65 (Ser536), NFκB p65, phospho-IKKα/β (Ser176/180), IKKα, IKKβ, NF κ B p50 and β -actin (Cell Signaling Technology, Beverly, MA), as identified in the figures. Immunoreactive bands were visualized by enhanced chemiluminescence (Amersham Pharmacia Biotech) using horseradish peroxidase-conjugated IgG secondary antibodies.

REFERENCES


1. Schreiber E, Matthias P, Müller MM, Schaffner W: Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. *Nucleic Acids Research* 17: 6419, 1989.

Supplementary Figure 1. Representative FACS profiles of purified CD4⁺ T cells. For these, and all subsequent, studies presented as Supplementary Figures, CD4⁺ T cells were positively isolated from non-diabetic female NOD mice receiving NCD. FACS profile of CD4⁺ T cells from Spleen (A) and LN (C) in CD3⁺CD4⁺-gated events, and Thymus (B) in CD4⁺ CD8⁺-gated events.




©2010 American Diabetes Association. Published online at <u>http://diabetes.diabetesjournals.org/cgi/content/full/db09-1618/DC1</u>.


Supplementary Figure 2. Concentration dependent effects of sDPP-IV and incretins on the migration of CD4⁺ T cells. Splenic (A) or LN (B) CD4⁺ T cells isolated from non-diabetic female NOD mice were incubated with indicated concentrations of sDPP-IV, GIP or GLP-1. The migration of CD4⁺ T cells was determined using Transwell chamber (Corning) as described in *Experimental Procedures*. All data represent the mean \pm S.E.M. and significance was tested using ANOVA with a Newman-Keuls post hoc test, where ** represents p<0.05 *vs* Control.



Supplementary Figure 3. Islet localization of labeled splenic (A-D) and LN (E-H) CD4⁺ T lymphocytes following sDPP-IV or incretin stimulation. splenic^{Up} and splenic^{Low} (A-D) and LN^{Up} and LN^{Low} (E-H) = Splenic or LN lymphocytes from upper and lower chambers, respectively. Mixtures of DiI- and CFSE- labeled splenic (A-D) and LN (E-H) CD4⁺ T lymphocytes were intravenously injected into diabetic recipient mice and pancreatic homing of labeled lymphocytes determined by confocal fluorescent microscopy. Infiltrated islets are represented with an *i*, and the scale bar indicates 25 μ m.




Α.




4

©2010 American Diabetes Association. Published online at http://diabetes.diabetesjournals.org/cgi/content/full/db09-1618/DC1.




5


 $\label{eq:solution} \ensuremath{\textcircled{\scale}}\xspace{1.5} 2010 \ensuremath{\scale}\xspace{1.5} and \ens$



F.




©2010 American Diabetes Association. Published online at http://diabetes.diabetesjournals.org/cgi/content/full/db09-1618/DC1.



G.

Supplementary Figure 4. The effect of Sitagliptin on phosphorylation levels of cytoskeletal organizing protein in thymic and LN CD4⁺ T cells. CD4⁺ T cells were stimulated for 1 h with sDPP-IV (100 mU/ml), GIP or GLP-1 (100 nM) in the presence or absence of DPP-IV inhibitor (100 μ M). Total cellular extracts were isolated from thymic (A-D) or LN (E-H) CD4⁺ T cells and Rac1 activation assays (A, E) or Western blot analyses performed with antibodies against phospho-VASP (Ser157) (B, F), Phospho-Ezrin (Thr567)/Radixin (Thr564)/Moesin (Thr558), Ezrin/Radixin/Moesin (C, G), phospho-Cofilin (Ser3), Cofilin (D, H), and β -actin. Western blots are representative of n = 3.



В.

p-VASP (Ser-157) →

β-actin →

GIP (100 nM):	-	_	_	+	+	_	-
GLP-1 (100 nM):	-	_	_	_		+	+
DPP-IV (100 mU/ml):	-	+	+	-	Ι	_	-
Sitagliptin (100 µM):	١	_	+	-	+	-	+

$\hat{}$	
C	

p-Ez (Thr-	rin (Thr-567)/ Radixin 564)/ Moesin (Thr-558) ⊏	-	_	-	-	_	_	-
	Ezrin/ Radixin/ ⊏ Moesin		-	-	-	-	-	-
	GIP (100 nM):	-	-	_	+	+	-	-
	GLP-1 (100 nM):	1	_	_	_	-	+	+
	DPP-IV (100 mU/ml):	_	+	+	-		-	_
	Sitagliptin (100 µM):	_	-	+	_	+	-	+

D.

p-Cofilin (Ser-3) →	-	-	-	-	-	-	-
Cofilin →	_	_		_		_	_
GIP (100 nM):	_	_	_	+	+	_	_
GLP-1 (100 nM):	-	_	_	_	-	+	+
DPP-IV (100 mU/ml):	1	+	+	—	-	-	-
Sitagliptin (100 µM):	١	-	+	-	+	-	+

Ε.

GTP-Rac1 →	-	-	-	-		-	-
Rac1 in lysates→	-	_	-	-	_	_	-
GIP (100 nM):	-	_	-	+	+	-	_
GLP-1 (100 nM):	_	-	_	_	-	+	+
DPP-IV (100 mU/ml):	-	+	+	-		-	-
Sitagliptin (100 µM):	1	-	+	-	+	-	+

F.

p-VASP (Ser-157) →		_	_		_	_	_
β-actin →	_			_	_	_	_
GIP (100 nM):	-	_	_	+	+	_	_
GLP-1 (100 nM):	-	_	_	_	_	+	+
DPP-IV (100 mU/ml):	-	+	+	-	-	-	-
Sitagliptin (100 µM):	١	-	+	-	+	-	+


G.

rin (Thr-567)/ Radixin 564)/ Moesin (Thr-558) ⊏	-	-	-	-	-	-	
Ezrin/ Radixin/ ⊏ Moesin		-	-	-	-	-	-
GIP (100 nM):	_	_	_	+	+	_	-
GLP-1 (100 nM):	_	_	-	_	_	+	+
DPP-IV (100 mU/ml):	—	+	+	_	_	-	-
Sitagliptin (100 µM):	-	_	+	_	+	_	+


Н.

p-Cofilin (Ser-3) →		_				_	_
Cofilin →				-	_	-	_
GIP (100 nM):	_	_	_	+	+	_	_
GLP-1 (100 nM):	-	-	_	-	_	+	+
DPP-IV (100 mU/ml):	-	+	+	-	-	-	-
Sitagliptin (100 µM):	I	-	+	_	+	1	+


Supplementary Figure 5. The effect of Rac1 inhibitor and PKA inhibitor on the phosphorylation of cytoskeletal organizing protein Ezrin (Thr567)/Radixin (Thr564)/Moesin (Thr558) and Cofilin (Ser3). Splenic CD4⁺ T lymphocytes were stimulated for 1 h with DPP-IV (100 mU/ml) in the presence or absence of Rac1 inhibitor (100 μ M) or forskolin (10 μ M) ± H-89 (10 μ M) and total cellular extracts were isolated A-B. Effects of treatment with Rac1 inhibitor on the level of Ezrin (Thr567)/Radixin (Thr564)/Moesin (Thr558) (A) and Cofilin (Ser3) (B). C-D. Effect of treatment with H-89 on the level of Ezrin (Thr567)/Radixin (Thr564)/Moesin (Thr567)/Radixin (Thr567)/Radixin (Thr564)/Moesin (Thr558) (C) and Cofilin (Ser3) (D). Western blots are representative of n = 3.



В.						
p-Cofilin (Ser-3) →			-	-		-
Cofilin →						
β-actin →						
DPP-IV (100 mU/ml):		+	+	20		+
DPP-IV inhibitor (100 µM):	2		<u>ः</u> +	+	1	-
Rac1 inhibitor (100 µM):	12	<u>92</u> 22		1727	+	+



Supplementary Figure 6. The effect of Sitagliptin on phosphorylation levels of NF- κ B signalling modules in splenic and thymic CD4⁺ T cells. Total cellular extracts were isolated from splenic (A-C) or thymic (D-F) CD4⁺ T cells and stimulated for 1 h with sDPP-IV (100 mU/ml), GIP or GLP-1 (100 nM) in the presence or absence of DPP-IV inhibitor (100 μ M). Western blot analyses were performed with antibodies against phospho-IkB (Ser32), IkB (A, D), Phospho-NFkB p65 (Ser536), NFkB p65 (B, E), phospho-IKK α/β (Ser176/180), IKK α , IKK β (C, F), and β -actin. Western blots are representative of n = 3.



Β.

p-NFĸB p65 (Ser 536) →	-	_		-	_		_
NFĸB p65 →	-	-	-	-	-	-	-
β-actin →	_	-	_	-	-	-	_
GIP (100 nM):	-	_	_	+	+	_	_
GLP-1 (100 nM):	-	I	_	_	١	+	+
DPP-IV (100 mU/ml):	-	+	+	_			-
Sitagliptin (100 µM):	_	_	+	_	+	-	+

C. p-IKKα/β (Ser 176/180) →	O'res shed built from more price month
ΙΚΚα →	
ІККβ →	
β-actin →	
GIP (100 nM):	+ +
GLP-1 (100 nM):	+ +
DPP-IV (100 mU/ml):	- + +
Sitagliptin (100 µM):	+ - + - +
D. p-lκBα (Ser 32) →	
lκBα →	
β-actin →	
GIP (100 nM):	+ +
GLP-1 (100 nM):	+ +
DPP-IV (100 mU/ml):	- + +
Sitagliptin (100 µM):	+ - + - +
E. p-NFxB p65 (Ser 536) →	
NFκB p65 →	
β-actin → •	
GIP (100 nM):	+ +
GLP-1 (100 nM):	+ +
DPP-IV (100 mU/ml):	- + +
Sitagliptin (100 µM):	+ - + - +
F. p-ΙΚΚα/β (Ser 176/180) →	
IKKα →	
ІККβ → ∙	
β-actin → 1	
GIP (100 nM):	+ +
GLP-1 (100 nM):	+ +
DPP-IV (100 mU/ml):	- + +
Sitagliptin (100 µM):	+ - + - +